Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M958Revenue (TTM) $M300Net Margin (%)-10.1Altman Z-Score13.9
Enterprise Value $M872EPS (TTM) $-0.9Operating Margin %-9.4Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-8.9Higher ROA y-yY
Price/Book7.010-y EBITDA Growth Rate %--Quick Ratio3.7Cash flow > EarningsY
Price/Sales3.25-y EBITDA Growth Rate %--Current Ratio3.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-16.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-21.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M33.0ROIC % (ttm)-82.8Gross Margin Increase y-yN

Gurus Latest Trades with GHDX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GHDXDavid Swensen 2013-03-31 Sold Out -2.8%$26.72 - $29.65
($28.5)
$ 29.032%Sold Out0
GHDXDavid Swensen 2012-12-31 Buy 2.8%$26.42 - $36.8
($30.13)
$ 29.03-4%New holding37,861
GHDXDavid Swensen 2011-03-31 Sold Out -0.93%$21.08 - $26.18
($23.29)
$ 29.0325%Sold Out0
GHDXDavid Swensen 2010-12-31 Buy 0.93%$13.18 - $23.52
($17.74)
$ 29.0364%New holding38,243
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GHDX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


GHDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Shak StevenChief Scientific Officer 2016-07-19Sell5,000$27.425.87view
Cole G BradleyCOO 2016-07-06Sell5,000$26.648.97view
Shak StevenChief Scientific Officer 2016-06-21Sell5,000$25.7712.65view
Cole G BradleyCOO 2016-06-09Sell5,000$26.629.05view
Vaughn James JChief Commercial Officer 2016-06-06Sell1,997$283.68view
Cole G BradleyCOO 2016-05-16Sell5,000$27.65.18view
Febbo Phillip G.Chief Medical Officer 2016-05-10Sell6,324$27.26.73view
Vaughn James JChief Commercial Officer 2016-05-09Sell2,000$283.68view
Shak StevenChief Scientific Officer 2016-05-04Sell10,000$25.4314.16view
Vaughn James JChief Commercial Officer 2016-02-09Sell3$283.68view

Quarterly/Annual Reports about GHDX:

News about GHDX:

Articles On GuruFocus.com
CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares Jul 13 2012 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Mar 14 2011 
Genomic Health Inc. (GHDX) COO G Bradley Cole sells 2,500 Shares Mar 10 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Feb 14 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Jan 19 2011 

More From Other Websites
Genomic Health to Announce Second Quarter 2016 Financial Results and Host Conference Call on... Jul 26 2016
Genomic Health to Offer Epic Science's AR-V7 test, Shares Up Jul 11 2016
[$$] Test Aids Prostate Cancer Treatment Jul 08 2016
[$$] Test Aids Prostate Cancer Treatment Jul 06 2016
Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid... Jul 06 2016
Genomic Health, Inc. – Value Analysis (NASDAQ:GHDX) : July 5, 2016 Jul 05 2016
Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : July 4, 2016 Jul 04 2016
Genomic Health: Can the Liquid Biopsy Test Boost Margins? Jun 24 2016
GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 23 2016
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer Jun 17 2016
GENOMIC HEALTH INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 15 2016
Genomic Health Launches Oncotype SEQ™ Liquid Biopsy Mutation Panel Jun 14 2016
Nature Partner Journals Publish Five-year Outcomes Results from SEER Registry Demonstrating Oncotype... Jun 08 2016
Genomic Health Announces Multiple Oncotype DX® Presentations at ASCO 2016 Showcasing... Jun 05 2016
Genomic Health to Present at Jefferies 2016 Healthcare Conference May 31 2016
Genomic Health Announces Presentation of Seven Oncotype DX® Studies at the 2016 American Society of... May 26 2016
Genomic Health Announces Publication in Journal of Clinical Oncology Demonstrating Oncotype DX®... May 25 2016
Genomic Health (GHDX): Q1 Results Strong, Costs Escalate May 24 2016
ETF’s with exposure to Genomic Health, Inc. : May 19, 2016 May 19 2016
Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : May 19, 2016 May 19 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)